EULAR recommendations for the treatment of systemic sclerosis;EULAR-Empfehlungen zur Behandlung der systemischen Sklerose

Zeitschrift fur Rheumatologie

Volumn 69, Issue 1, 2010, Pages 87-92

  Schmeiser, T ^a   Muller Ladner U ^a,b  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b KERCKHOFF HEART CENTER   (Germany)

Author keywords

Calcium channel blocker; Cyclophosphamide; Endothelial receptor antagonists; Methotrexat; Prostaglandin; Steroids

Indexed keywords

BOSENTAN; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ILOPROST; METHOTREXATE; NIFEDIPINE; PROSTACYCLIN; SILDENAFIL; SITAXSENTAN;

ADRENAL DISEASE; CLINICAL RESEARCH; DELPHI STUDY; HUMAN; INTERSTITIAL LUNG DISEASE; PUBLICATION; PULMONARY HYPERTENSION; REVIEW; SKIN DISEASE; SYSTEMIC SCLEROSIS; TREATMENT INDICATION; ULCER;

EID: 77952743559     PISSN: 03401855     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00393-009-0467-x     Document Type: Review

References (22)

1. Walker UA, Tyndall A, Czirják L et al (2007) Clinical risk assessment of organ manifestations in systemic sclerosis - a report from the EULAR Scleroderma Trials and Research (EUSTAR) group data base. Ann Rheum Dis 66:754-763 (Pubitemid 46846694)
2. Hunzelmann N,Genth E, Krieg T et al (2008) for the German Network for Systemic Scleroderma. The registry of the German Network for Systemic Scleroderma: Frequency of disease subsets and patterns of organ involvement: Rheumatol 47:1185-1192
3. Thompson AE, Shea B, Welch V et al (2001) Calciumchannel blockers for Raynaud's phenomenon in systemic sclerosis. Arthritis Rheum 44:1841-1847 (Pubitemid 32758232)
4. Pope J, Fenlon D, Thompson A et al (2007) Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis. Cochrane Libr 1: 1-16
5. Korn JH, Mayes M, Matucci-Cerinic M et al (2004) Digital ulcers in systemic sclerosis. Prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 50:3985-3993
6. Seibold JR, Matucci-Cerinic M, Denton CP et al (2006) Bosentan reduces the number of new digital ulcers in patients with systemic sclerosis. Ann Rheum Dis 65 (Suppl II): 90
7. Rubin LJ, Badesch DB, Barst RJ et al (2002) Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346:896-903 (Pubitemid 34984638)
8. Barst RJ, Langleben D, Frost A et al (2004) Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 169:441-447 (Pubitemid 38187114)
9. Wilkins MR, Paul GA, Strange JW et al (2005) Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. Am J Respir Crit Care Med 171:1292-1297 (Pubitemid 40740738)
10. Liu C, Chen J (2006) Endothelin receptor antagonists for pulmonary arterial hypertension. Cochrane Database Syst Rev 3:CD004434
11. Denton CP, Humbert M, Rubin L, Black CM (2006) Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: A subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis 65:1336-1340 (Pubitemid 44620443)
12. Barst RJ, Langleben D, Badesch D et al (2006) Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 47:2049-2056
13. Galie N, Ghofrani HA, Torbicki A et al (2005) Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353:2148-2157 (Pubitemid 41653106)
14. Pope JE, Bellamy N, Seibold JR et al (2001 ) A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 44:1351-1358 (Pubitemid 32537533)
15. Tashkin DR Elashoff R, Clements PJ et al (2006) Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354:2655-2666
16. Hoyles RK, Ellis RW, Wellsbury J et al (2006) A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 54:3962-3970 (Pubitemid 44955900)
17. Steen VD, Costantino JR Shapiro AR Medsger TA Jr (1990) Outcome of renal crisis in systemic sclerosis: Relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med 113:352-357
18. DeMarco PJ, Weisman MH, Seibold JR et al (2002) Predictors and outcomes of scleroderma renal crisis: The high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum 46:2983-2989 (Pubitemid 35315892)
19. van Pinxteren B, Numans ME, Bonis PA, Lau J (2006) Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 3:CD002095
20. Verne GN, Eaker EY, Hardy E, Sninsky CA (1995) Effect of octreotide and erythromycin on idiopathic and scleroderma-associated intestinal pseudoobstruction. Dig Dis Sci 40:1892-1901
21. Soudah HC, Hasler WL, Owyang C (1991 ) Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. N Engl J Med 325:1461-1467
22. Karamanolis G, Tack J (2006) Promotility medications-now and in the future. Dig Dis 24:297-307